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In spite of decades of investigation, the etiology(ies) of rheumatoid arthritis (RA) 1 
and  many  of  the  related  rheumatic  diseases  remains  unknown.  One  hypothesis 
suggests  that  certain  poorly degradable bacterial peptidoglycans are transported  to 
the joint and are capable of instigating an abnormal immune response on the part of 
the host  (1,  2). The resultant  inflammatory response by the host is self-perpetuating 
and leads to the destruction of the joint. This viewpoint is supported by the observation 
that  there  is  an  increased  humoral  response  to  bacterial  mucopeptide  antigens  in 
juvenile RA patients (3, 4) and at least one report (5) of increased antibodies in adult 
RA patients. 
Experimentally, a  number  of investigators  (reviewed by  Schwab  et  al.  [6])  have 
demonstrated certain forms of chronic relapsing arthritis in animals using multiple or 
single injections of microbial antigens. In a  rat model of arthritis (7, 8),  intraperito- 
neally injected sonicated cell wall material from the group A  streptococcus has been 
found  to  localize in  the joint,  initially being  found  extracellularly as well as inside 
phagocytic  cells.  As  the  arthritis  became  chronic,  the  material  was  found  in  the 
synovium predominantly inside the macrophages. The bacterial cell wall is composed 
of  various  polysaccharides  linked  to  a  peptidoglycan  backbone,  and  the  relative 
nonbiodegradability of bacterial peptidoglycan appeared to be an important  patho- 
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genic factor. Sonication of the cell wall material greatly enhanced its arthritogenicity. 
The synthetic adjuvant, N-acetylmuramyl-L-alanyl-D-isoglutamine, (muramyl dipep- 
tide, or MDP), which  forms a  part of the monomer of the peptidoglycan portion of 
bacterial cell walls, can also be arthritogenic in rats if administered appropriately (9). 
Local  release  of proteolytic  enzymes  such  as  plasmin  and  collagenase  could  be 
responsible for some of the tissue damage and vascular effects associated with RA (10, 
11). Plasmin  is generated after interaction  of another neutral  protease plasminogen 
activator (PA), with its substrate, plasminogen (P). The PA/plasmin system has been 
detected  in  cultures  of  enzyme-dissociated  rheumatoid  tissue  (10).  Plasmin  can 
degrade  basement  membrane  (12)  and  cartilage  (13)  and  activate  both  a  latent 
collagenase  (10)  and also certain enzyme cascades likely to be of importance in  the 
development  of inflammatory responses  (14-16).  It  was  reported  that  conditioned 
medium  (CM)  from  normal  human  peipheral  blood  mononuclear  cells  (PBMC) 
elevated the PA activity of passaged nonrheumatoid human synovial fibroblasts (t 1), 
and more recently of the passaged rheumatoid counterparts. 2 This modulation of the 
synovial cell PA activity by mononuclear cells (MC)  was proposed as being part of 
the  cellular  interactions  contributing  to  the  properties  of the  aggressive,  invasive, 
rheumatoid  "pannus"  (11).  The activity in  the  mononuclear  cell  CM  (MCCM)  is 
here termed synovial activator (SA) activity. 
We  report  here  the  PBMC,  when  treated  either  with  cell  wall  sonicate  (CWS) 
material  from  several  group  A  streptococcus  strains  or  also  with  MDP,  generate 
elevated  levels  of SA  activity.  The  CWS  are  most  likely  acting  via  a  monocyte- 
macrophage in the PBMC. Preliminary evidence indicates that SA activity is distinct 
from interferon-3,, interleukin  1 (IL-1), and interleukin 2 (IL-2). Thus, SA activity can 
be  generated  in  vitro  by  structures  which  are  both  known  to  be  arthritogenic  in 
animals (7, 8)  and to be also implicated in RA (2-5). 
Materials and Methods 
Synovial Cell Culture.  As previously described (11), synovial  membrane tissue was obtained 
aseptically  from  the  knees  of normal  patients,  i.e.,  patients  free  of known  rheumatoid  or 
degenerative joint disease, needing correction of internal derangements, for example, by means 
of meniscectomy. Synovial tissue  from the hips or knees of patients with degenerative joint 
disease  was obtained during prosthetic joint  replacements. Synovial cells from these  sources 
have similar growth and biochemical parameters (17). The techniques used for the culture of 
human synovial fibroblast-like cells from explant tissue were essentially  those of Castor et al. 
(t7)  and  have  been  outlined  previously (11). The  passaged cells  are morphologically and 
biochemically similar to the fibroblast-like cells studied by Castor et al. (17). 
Preparation of Streptococcal CWS.  The following group A streptococcal strains were obtained 
from The Rockefeller  University collection:  $43/100  (type 6), T12/126 (type 12), D678  (type 
11), and A995 (type 57). These were grouped and typed by the Lancefield method, and the cell 
walls isolated  by methods previously described  (18). CWS were prepared by the technique of 
Cromartie  et  al.  (7), and  were  the  materials  used  in  the  current  study.  The  CWS  were 
resuspended by vortex mixing in  phosphate-buffered saline  (PBS) (0.01 M  phosphate buffer 
(pH 7.4), 0.15 M NaC1 [19]). MDP was obtained from Dr. D. Braun, Ciba-Geigy Ltd., Basel, 
Switzerland,  and dissolved in PBS before use. 
Preparation of MCCM.  For  the  preparation  of MCCM,  PBMC  from  citrate  phosphate 
dextrose-treated venous blood of normal donors or from normal blood depleted of platelets, 
erythrocytes, and plasma were separated on Ficoll-Hypaque gradients (Pharmacia Fine Chem- 
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icals, Div. of Pharmacia Inc., Piscataway, N  J)  (11). Varing numbers of the MC were cultured 
at  37°C in an atmosphere of 5% CO2 and 95% air in duplicate 35-mm Diam tissue culture 
dishes  (3001, Falcon Labware, Oxnard, CA) usually for 24-48 h, either in  1 ml a-minimum 
essential medium '(a-MEM)  alone or  in the  presence of various stimuli, particularly CWS 
preparations.  MCCM  were  collected after centrifugation of the cells  and stored  at  -20°C 
before assay of the SA activity. 
Measurement of SA Activity.  The SA activity in MCCM preparations was  measured as the 
ability to  elevate the  PA levels  of target  human synovial fibroblasts. For this purpose,  the 
fibroblasts were plated at  104 cells/0.2 ml in 12sI-fibrin-coated  wells of Costar 96-well  tissue 
culture  plates  (3596;  Costar,  Data  Packaging,  Cambridge,  MA),  prepared  as  previously 
described (19).  2 After incubation for 24-96 h in a-MEM containing 7.5% heat-inactivated (60 
min, 56°C)  fetal bovine serum (FBS)  and 7.5% heat-inactivated newborn bovine serum, the 
cultures were washed twice with a-MEM and placed in a-MEM (100/~1) containing different 
MCCM preparations (40/~1) and supplemented with 5% of acid-treated FBS (ATFBS) (20) or 
5% P-depleted ATFBS (ATFBS-P) (21). P was removed from the FBS by passage through a 
Sepharose-lysine affinity column (21); this procedure has been shown to remove ~97% of the 
original concentration  of P (20) and allows determination  of the P dependence of the fibrinolytic 
activity. FBS was acidified (then neutralized) for this assay to remove inhibitors of fibrinolysis 
(20). Aliquots (40 p.l) of the supernatant medium were taken from duplicate cultures at 24 or 
48 h and assayed for solubilized radioactivity as a measure of fibrinolytie activity (11, 19). 
Data from individual experiments are provided. Range of variation from duplicate cultures 
is  10-15%  of the  mean value. Serial dilutions of MCCM  preparations were always used to 
ensure that any fibrinolytic activity was on the linear range of a dose-response curve for SA 
activity. The fibrinolytic  activities shown are the P-dependent values (i.e., PA activities) because 
the P-independent fibrinolytic activities never amounted to more than 10% of this value (11). 
The PA activities measured are not from the MCCM themselves but require the interaction 
between the MCCM and the synovial cells (11). 
Cell Separation 
ADHERENCE AND PHAGOCYTOSIS.  PBMC were plated in 1 ml a-MEM +  10% FBS for  1.5 h 
at 37°C in 35-mm dishes. The nonadherent cells were removed aseptically by a pasteur pipette 
and resuspended  (3  ×  [06/ml)  in a  at-MEM  +  10%  FBS containing excess carbonyl iron- 
lymphocyte reagent (Technicon Instruments  Corp., Tarrytown, NY) to deplete them of residual 
phagocytic cells. For this purpose, the cells were  rotated gently for 30 min at 37°C, the iron 
carbonyl removed by a magnet, and the cells washed in medium (22). The adherent cells were 
washed once with a-MEM before use, and any weakly adherent cells removed by this washing 
were discarded. The remaining adherent cells were _~95% monocyte-macrophages by morphol- 
ogy  (Wright-Giemsa stain)  and  by the  ability (~90%)  to  phagocytize latex  particles  (1-#m 
Diam, The Dow Chemical Co., Indianapolis, IN) (23). 
T-CELL AND B-CELL DEPLETION.  PBMC were depleted of T  lymphocytes by the commonly 
used method of E-rosette formation with neuraminidase-treated  sheep erythrocytes followed by 
centrifugation (24). After shock lysis oferythrocytes with ammonium chloride, T cells were also 
recovered by a procedure previously described (24). PBMC were depleted of B lymphocytes by 
the widely used method involving immunoglobulin-coated  sheep erythrocytes (25). This was 
carried out in the laboratory of Dr. N. Chiorazzi of The Rockefeller University. 
Lysozyme Assay.  Lysozyme in the MCCM samples was assayed (26) by measuring the initial 
rate  of lysis of a  suspension of Micrococcus luteus (Difco  Laboratories,  Detroit,  MI).  Human 
lysozyme (Dr. E. Osserman, College of Physicians and Surgeons of Columbia University, New 
York), diluted in a-MEM or a-MEM +  5% FBS, was used as a standard. 
Interferon (IFN)  Activity.  IFN titrations were done based on inhibition of the pathogenic 
effect of vesicular stomatitis virus (27). All samples were tested on human fibroblasts trisomic 
for  chromosome  21  and  on  bovine kidney cells.  On  every  96-well  plate  (Falcon  3040),  a 
laboratory standard of human IFN-a calibrated against  the  National  Institutes of Health 
standard  for  IFN-a  (G-023-901-527)  was  assayed.  The  IFN levels  of test  samples were  not 
adjusted to the IFN-a reference; however,  the reference varied not more than 0.5 logl0 units in 
different titrations. The majority of the IFN activity produced by human leukocytes in response 
to staphylococcus enterotoxin B (SEB) in vitro has been classified as IFN-y (28). ttAMILTON,  ZABRISKIE, LACttMAN, AND  CttEN  1705 
IL-2 Assay.  This was done by the method of Mier and Gallo (29), monitoring the ability of 
IL-2 to stimulate [3H]thymidine ([3H]TdR) incorporation into T  lymphoblasts. 
Preparation and Purification ofIL-I Samples.  Buffy coat cells were obtained after leukophoresis 
treatment of the peripheral blood of an acute myelomonocytic (AMML) patient (30). The CM 
was prepared from these cells cultured at 3 ×  106/ml in 5% normal human serum for 48 h' in 
the presence of 10 /~g/ml Escherichia coli lipopolysaccharide (LPS)  (strain 055:B5)  (28).  The 
biochemical properties of normal leukocyte IL-1 and leukemic cell IL-1 have been shown to be 
very similar (30). 
STAGE I PURIFICATION.  IL-1  activity in  the  leukocyte CM  can  be efficiently and  rapidly 
separated from  the majority of serum proteins by the procedure of hollow-fiber diafiltration 
and uhrafihration (31).  Briefly, IL-1 activity is separated from the serum proteins required for 
its preparation by  passage twice through  a  50,000-mol  wt  cut-off hollow  fiber device. This 
procedure removes >99% of the initial protein and results in a recovery of 80% of the =13,000- 
mol wt IL-1 activity. 
STAGE n  PURIFICATION.  Sucrose gradient isoelectric focusing (IEF) was performed on the 
sample from Stage I  (31).  IEF fractions in the pH range 6.8-7.2 were pooled, diluted 10-fold 
with  PBS, and  dialyzed overnight  to remove the remaining sucrose and  ampholine. IEF of 
hollow-fiber-purified IL-1  from  the AMML cell CM  revealed a  single peak of IL-I  activity 
with an average isoelectric point of 7.0 (30). 
STAGE In PURIFICATION.  The pooled stage III sample was further purified by semipreparative 
polyacrylamide gel electrophoresis in 7.5% gels as previously described (31). IL-l was recovered 
from the gel slices as a single peak of activity having an electrophoretic mobility at pH 8.60 of 
0.16  (tracking dye  =  1.00).  The  recovered IL-1  activity has  been  estimated to  be purified 
> 16,000-fold and has been judged to be active in submicrogram amounts. 
IL-1  Assay.  IL-1  was  measured  in  10-/d  samples  as  the  direct  stimulation  of  mouse 
thymocytes to incorporate [3H]TdR using the microassay previously published (31). All results 
are expressed as the average of triplicate cultures. The units of IL-1 activity have been described 
(31). That the activity is due to IL-1, and not IL-2, is always checked by assaying for IL-2 (see 
above): if no IL-2 is present, then the thymocyte assay is monitoring IL-I. 
Determination of the Properties of SA Activity.  Pooled fractions with SA activity from a Sephadex 
G-100  column  were  dialyzed against  10  mM  sodium  phosphate,  pH  7.4,  lyophilized, and 
adjusted with H20 to l0 times the concentration. This concentrated sample was aliquoted and 
stored at -20°(2 before use. 
Results 
Generation of SA Activity by Streptococcal Cell Wall Sonicates.  It was recently reported 
(11)  that  concanavalin  A  (Con  A)  elicits SA activity from  human  PBMC  in  both 
serum-free and FBS-containing cultures. Given that streptococcal cell wall fragments 
can  be  arthritogenic  in  rats  (8),  and  that  streptococci  could  belong  to  a  class  of 
possible etiologic agents  for  RA  (2-5),  group  A  streptococcal cell wall preparations 
were tested as generators of SA activity from  PBMC.  In Fig.  1, it can be seen that a 
sample of type 6  (T6)  CWS  (1-100 #g/ml)  was active in both serum-free and  FBS- 
containing medium. 
As presented in Fig. 2, CWS from three other group A streptococcal strains, namely 
type 12  (T12), type  11  (T11), and type 57  (T57), were also active, the data presented 
being for serum-free medium. In other experiments, the T6 and T12 CWS were found 
to  have  comparable  activity both  in  terms  of the effective doses and  the  degree of 
stimulation attained. None of the CWS elevated the PA activity of the synovial cells 
directly. As can be observed in  Fig. 2, adherent  cells from the PMBC  were a  source 
of the  SA activity; a  more detailed analysis of the cell types responsible for the SA 
activity is provided below. For the total PBMC  and for the adherent subpopulation, 
all of the CWS were stimulatory over the approximate range  1-100 ~g/ml. 1706  STREPTOCOCCAL  CEI,L  WALLS  AND  SYNOVIAL CELL  ACTIVATION 
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FIo.  1.  Dose response for T6 CWS generation of SA activity.  Human synovial fibroblasts (2nd 
passage)  from an  osteoarthritie  donor  (B.S.)  were plated  in  12~I-fibrin coated  wells,  and  the  PA 
activity measured after 24 h  in the presence of the different  MCCM  preparations (Materials and 
Methods). MCCM were prepared from 4 ×  106 PBMC in 24-h cultures. MCCM prepared in  ! ml 
c~-MEM  (C)); MCCM prepared in  1 ml a-MEM +  5% FBS (Q). The doses ofT6 CSW shown are 
the final concentrations (/.tg/ml)  in  these MCCM cultures. The mean fibrinolytic activities  in the 
wells containing t~-MEM,  c~ +  5% FBS,  or 30/zg/ml T6 CWS as controls were all 0.1%. 
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Fie.  2.  Generation  of SA  activity  by  CWS of different  group A  streptococcal  strains.  Human 
synovial  fibroblasts  (5th  passage)  from an  osteoarthritic  donor  (B.S.)  were plated  in  msI-fibrin- 
coated  wells,  and  the  PA  activity  measured after  48  h  in  the  presence of the  different  MCCM 
preparations  (Materials  and  Methods).  (a)  T12  CWS;  (b)  TII  CWS;  (c)  T57  CWS.  MCCM 
prepared from 4  ×  106  PBMC  in 48-h cultures in  1 ml 0~-MEM  (  );  MCCM  prepared in the 
same way  but  from  the  adherent  cells  remaining after  the  1.5-h  adherence  of 4  X  106  PBMC 
followed by washing twice with o~-MEM (- -  -)  (Materials and Methods). The doses depicted are 
the final concentrations (/.tg/ml)  of the different CWS present in these MCCM cultures. The mean 
fibrinolytic activities in the wells containing a-MEM or 30/Zg/ml of each of the CWS materials as 
controls were 9%. 
Other stimuli for enhanced SA activity from PBMC (2-4 X  106 cells) in either 1 ml 
serum-free or in 5% FBS-containing medium include Con A (I-30/~g/ml [11], Miles- 
Yeda,  Rehovot,  Israel),  phytohemagglutinin  (0.1-1%  vol/vol, Wellcome  Reagents 
Ltd., Beckenham, England) and E. coli LPS (1 ng-10/zg/ml, strain 055:B5). HAMILTON,  ZABRISKIE,  LACHMAN,  AND  CHEN  1 707 
Generation of SA  Activity  by  MDP.  Previous  reports  have  demonstrated  that  the 
effects of bacterial cell wall preparations  can often be reproduced  by molecules of N- 
acetylmuramic  acid  residues  linked  to  small  peptide  structures  (32,  33),  which  are 
similar to the repeating  structures that  go to build up the peptidoglycan  structure  (2). 
In  fact,  MDP  has  been  shown  to  be  arthritogenic  in  rats,  provided  the  correct  oil 
vehicle was  included  during  injection  (9).  In  Fig.  3,  MDP  is seen to be potent  (on a 
weight  basis)  at  generating  SA  activity  from  adherent  cells  from  PBMC  in  the  two 
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FIG.  3.  Dose response for MDP generation of SA activity. Human synovial fibroblasts were plated 
in 1251-fibrin-coated wells. For experiment 1, the cells were from a normal donor (S.O.,  3rd passage), 
whereas for experiment 2, the cells were from an osteoarthritic donor (B.H.,  6th passage).  The PA 
activity was measured after 48 h  in the presence of the different MCCM preparations (Materials 
and Methods). MCCM were prepared from 48-h cultures of the adherent cells remaining after the 
1.5-h adherence of 4 ×  106 PBMC (Fig.  2). Data from the two separate experiments are provided: 
experiment  1, (©, O); experiment 2 (17, m). Open symbols indicate MCCM prepared in  1 ml a- 
MEM; closed symbols indicate MCCM in 1 ml a-MEM +  5% FBS. The doses of MDP shown are 
the final concentrations (ng/ml) in these MCCM cultures. The mean fibrinolytic activities in the 
wells  containing a-MEM,  a-MEM  +  5%  FBS,  or  300  ng/ml  MDP  as  controls were  0.5%  for 
experiment 1 and 2% for experiment 2. 
FIc,.  4.  Mononuclear cell number and SA activity. Human synovial fibroblasts (4th passage)  from 
a normal donor (G.G.) were plated in ]2'~I-fibrin-coated wells, and the PA activity measured after 24 
h  in the presence of the different MCCM preparations (Materials and Methods). Solid columns: 
MCCM  prepared  from different  numbers of PBMC  from  48  h  cultures in a-MEM  +  5~7,, FBS; 
stippled columns: MCCM prepared in the same way but in a-MEM +  5% FBS containing 30 #g/ 
ml  T6  CWS  (Materials and  Methods).  The  mean  fibrinolytic activities ill  the wells  containing 
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FIG.  5.  Adherent cell generation of SA activity. Human synovial fibroblasts  (6th passage) from an 
osteoarthritic donor (O.H.)  were plated in  t25I-fibrin-coated  wells, and  the PA activity measured 
after 24 h  in the presence  of the different MCCM preparations  (Materials and Methods).  "MC" 
refers to the total PBMC population and "nonadherent  MC" refers to the nonadherent  cells left 
after also removing phagocytic cells by the iron carbonyl treatment (Materials and Methods).  The 
"cell number" in each case refers to the number of these cells plated to generate the SA activity. 
"MC for adherence" refers to the MC plated for the 1.5-h adherence step  (Materials and Methods) 
and "cell number" in this case means the number of these cells plated to generate the adherent cells. 
Solid columns: CM from the various cell populations were prepared in a-MEM + 5% FBS from 24- 
h cultures.  Hatched and stippled columns: CM were prepared in the same way but in a-MEM + 
5%  FBS supplemented  with  10 btg/ml  TI2  CWS or T6  CWS,  respectively  (see Materials  and 
Methods).  The mean fibrinolytic activities  in the wells containing media or 3/Lg/ml TI2 CWS or 
3/Lg/ml T6 CWS, as controls  were all 0.2% (data not shown).  Open columns: lysozyme was also 
measured in the CM prepared  in a-MEM +  5% FBS; the values  refer to the mean total enzyme 
activity in the duplicate cultures. 
separate  experiments.  The  MDP  sample  was  active  in  both  serum-free  and  in  FBS- 
containing medium  even at  concentrations  as  low as 0.1  ng/ml.  In  the same experi- 
ments,  >1  #g/ml  T6 CWS  was  required  to elicit SA activity, but  the  maximum  SA 
activity that  could be generated  from optimal  concentrations  of MDP  and  T6 CWS 
was similar (data not shown).  Thus,  the arthritogenic  MDP  structure  is also active in 
the in vitro model system  under study. 
Cell Number and SA  Activity.  In  Fig.  4,  the  relationship  of PBMC  number  to  SA 
activity  resulting  from  T6  CWS  action  is  plotted.  SA  activity can  still  be  detected 
from 5  ×  105/ml  PBMC  and  is still increasing  at  a  cell concentration  of 4  X  106/ml 
a-MEM  +  5% FBS.  A  similar cell dose response  is evident in serum-free  medium  or, 
if the stimulus  is either  1 /~g/ml MDP  or  10 #g/ml  Con  A, in  serum-free or in  FBS- 
containing medium  (data  not  shown). 
Cell Type and SA Activity.  As mentioned  above  (Figs.  2  and  3),  adherent  cells from 
PBMC  could  elicit  SA activity in  response  to  streptococcal  CWS  and  MDP.  Fig.  5 
shows  more  data  in  which  total  PBMC,  adherent  cells,  and  the  nonadherent, 
nonphagocytic  (i.e.,  iron  carbonyl-treated)  populations  (see  Materials  and  Methods) 
are compared  as sources of SA activity in response  to FBS, T12  CWS,  and  T6 CWS 
in  the same experiment.  The  number  of adherent  cells obtained  by  this procedure  is 
of the order of 10-20% of the total MC  population.  As can be noted, the adherent  cell 
population  was  the  most  active  on  a  per  cell  basis  as  a  source  of SA  activity.  As 
monocyte-macrophages  are  the  predominant  cell  type  present  in  the  adherent  cell 
cultures  derived  from  the  PBMC,  these  data  would  suggest  that  this  cell  class  is 
responsible  for  the  SA  activity.  Supporting  this  statement  are  the  lysozyme  levels 
monitored  in  the  various  CM  from  the  FBS-containing  cultures.  Lysozyme  is  a 
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those  which  arise  from a  cell  population  with  the  higher  levels of lysozyme in  the 
control (i.e.,  FBS) cultures. 
This type of experiment has been repeated with >20 donors. In several experiments, 
the nonadherent cells (even sometimes after subsequent phagocytosis of iron carbonyl) 
had  appreciable  SA  activity,  and  this  was  particularly  noticeable  when  Con  A  or 
PHA was the stimulus.  However, when  these same CM  were assayed for lysozyme 
activity, then  it  was  found  that  the  most  potent  SA-containing  CM  had  the  most 
lysozyme. These data  suggest  that  the  number of monocyte-macrophage-type cells 
present  in  a  nonadherent  population  can  be quite  variable and  in  some cases can 
comprise  an  appreciable  percentage  of the  original  number.  This  observation  has 
been made by others (35)  and can depend on variables such as the PBMC donor and 
the serum used to attach the cells. For the adherent cells themselves, it is difficult to 
exclude the presence of a few contaminating, nonmonocyte, adherent cells that could 
be contributing  to the  SA levels.  SA activity could also be elicited  from T6 CWS- 
treated adherent cells after a  24-h adherence of PMBC  (data not shown). 
As  an  alternative  approach,  PBMC  were  enriched  for T  lymphocytes  (T  +)  and 
screened  together  with  the  T  lymphocyte-depleted cells  (T-).  The  data  in  Fig.  6 
demonstrate that T + cells were poor producers of SA activity, with the T- cells being 
enriched  for both  SA  and  lysozyme activity.  The adherent  cells were again  active 
both from the total PBMC (Fig. 6) and when obtained in turn from the T- population 
(data not shown). In a  separate experiment, if B lymphocytes were depleted directly 
from the PBMC  (Materials and Methods), then no loss of SA activity with 5% FBS, 
T6 CWS, and Con A occurred on a per cell basis (data not shown). The results in Fig. 
6 are consistent with those of Fig. 5 and suggest that cells belonging to the monocyte- 
macrophage subclass can be directly responsible for the SA activity. 
Kinetics of SA Generation.  The rate of appearance of the SA activity from adherent 
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Fro.  6.  T  cell  depletion and SA activity. Human synovial fibroblasts (lst passage) from a normal 
donor (R.W.) were plated in 12'~I-fibrin coated wells, and the PA activity measured after 24 h in the 
presence of the different  MCCM  preparations (Materials and Methods). "MC" refers to the total 
PBMC  population;  as  before,  "MC  for adherence"  indicates  MC  plated  for a  1.5-h  adherence; 
"T-" and "T  +'' refer to T  lymphocyte-depleted and -enriched populations, respectively (Materials 
and  Methods). Solid columns: CM from the various cell  populations were prepared in ot-MEM + 
5% FBS from 24-h cultures. Hatched and horizontal columns: CM were prepared in the same way 
but in a-MEM +  5% FBS supplemented with  10 ~g/ml TI2 CWS or 10 ~g/ml Con A, respectively 
(see Materials and Methods). The mean fibrinolytic activities in the wells containing media, 3 ,ug/ 
ml T12 CWS, or 3 #g/ml Con A as controls were ~7+7< (data not shown). Open columns: lysozyme 
was also measured in the CM prepared in a-MEM +  5+7, FBS:  the values refer to the mean total 
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cells in a-MEM +  5% FBS in response to T6 CWS is presented  in  Fig.  7.  Increased 
SA activity was easily detectable at  12 h, with plateau levels reached by 48 h. Similar 
kinetics were observed in a-MEM  +  5%  FBS and  also with Con  A  (5/~g/ml)  in a- 
MEM  +  5% FBS.  With some cultures, plateau levels were reached within  24 h.  SA 
levels at  earlier  time points  and  monocyte-macrophage metabolic requirements  for 
the formation of the SA activity are currently under study. 
Properties of SA Activity.  In this section, preliminary data from experiments designed 
to characterize the SA activity are included. 
GEL CHROMATOGRAPHY.  The SA activity in MCCM prepared in a-MEM alone or 
in a-MEM containing 5/~g/ml Con A was completely retained, and therefore could 
be concentrated by ultrafiltration with an Amicon UM-10 membrane (Amicon Corp., 
Scientific Systems Div., Lexington, MA). The concentrated CM from Con A-contain- 
ing  cultures  was  then  applied  to  a  Sephadex  G-100  column,  and  the  SA  activity 
appeared in the range of 28,000-34,000  mol wt.  (Fig. 8). 
Seeing that both IL-1 and IL-2 have been found in the CM from PBMC  (29,  31), 
the ability of the various fractions from this column to stimulate [3H]TdR incorpo- 
ration with  mouse thymocyte cultures was monitored  (see Materials  and Methods). 
The  main  peak of thymocyte-stimulating activity was at  ~20,000  tool wt  and  was 
clearly separate from the SA activity (data not shown, but see Fig. 9). The thymocyte 
assay does not distinguish between IL-1 and IL-2 (36). 
Several  stimuli,  such  as  antigens  (37)  and  mitogens  (38,  39),  are  able  to  act  as 
inducers,  from T  lymphocytes and/or  macrophages, of a  subclass of IFN known as 
IFN-y. Another  potent  inducer  of IFN-y is  SEB  (28).  In Fig.  9,  the IFN-y and  SA 
activity profiles after Sephadex G-100 chromatography for leukocyte CM prepared in 
the presence of FBS and SEB are provided. The SA activity is again in the range of 
25,000-34,000  mol wt with the molecular weight of the IFN-T being ~38,000-45,000 
(28).  Thus the molecular weight range for the SA activity in serum-free medium (Fig. 
8)  is  similar  to  that  in  FBS-containing  medium  (Fig.  9).  The  fact  that  IFN-  T  is 
unstable  (39), whereas SA is stable (see below) if stored overnight at pH 2 at 4°C, is 
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Fie,.  7.  Kinetics of appearance of SA activity. This was the same experiment as in Fig. 4, with the 
MCCM  being harvested at different time points and a constant number of the same MC population 
(4  ×  10  ~)  used  to  prepare  the  CM.  MCCM  prepared  in  1  ml a-MEM  +  5%  FBS  (O);  MCCM 
prepared  in  the  same  way  but  in  1  ml a-MEM  +  5%  FBS  containing 30 ~g/ml  T6  CWS  (O) 
(Materials and Methods).  The mean fibrinolytic activities in the wells containing media or  10 ~g/ 
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FIC. 8.  Purification of SA  activity by  gel  chromatography. Human synovial fibroblasts (3rd 
passage) from an osteoarthritic donor (L.F.) were plated in 125I-fibrin  coated wells, and the PA 
activity measured after 48 h in the presence of the different column fractions (40-/d) (see Materials 
and Methods). The cultures were also supplemented with 50/*g/ml gentamycin. The fractions for 
assay were obtained as follows. The 24-h serum-free CM (200 ml) prepared by stimulation of 4 × 
106 PBMC/ml  with 5 #g/ml Con A (Materials and Methods) was concentrated at 4°C to  10 ml 
using an Amicon UM-10 ultrafiltration membrane. 8 ml of this concentrated sample was loaded 
onto a 2.6 cm × 78 cm Sephadex G-100  column equilibrated with 20 mM sodium phosphate buffer, 
0.15 M  NaCI, pH  7.2. 7-ml fractious were collected every 45 rain; absorbance at  280 nm was 
recorded during the run. The absorbance was ~0.03 U near the void volume (fraction 18) and 
background values for the remaining fractions. Molecular weight standards were run consecutively 
under  the  same conditions (bovine serum albumin (BSA), 67,000; ovalbumin,  (OVA) 43,000; 
chymotrypsinogen A (CHY), 25,000; cytochrome C (CYT), 12,500). Each fraction was assayed in 
duplicate;  the  linearity of the  response for each fraction was checked by monitoring fourfold 
dilutions of the fractions. The mean fibrinolytic activities in the wells containing the column buffer 
and in the starting CM (diluted 1:20) as controls were 1.5% and 13%, respectively. 
consistent  with  this  chromatographic  separation.  The  effect  of  the  SEB  on  the 
generation of SA activity has not yet been studied, and the SA activity present in the 
experiment may have been due to stimulation by the FBS. 
The IL-2 activity profile was also monitored, with the main activity at  ~ 18,000- 
25,000 mol wt, and again being delineated from the peak of SA activity (Fig. 9).  In 
support of this preliminary biochemical distinction, it is perhaps worth noting that 
human  IL-2  is  generally considered to  be  a  T  lymphocyte product  (40)  although 
monocyte-macrophages appear to regulate its production (41). 
SA  ACTIVITY IN  PURIFIED IL-l.  IL-1  from  monocytes  has  been  implicated  as  a 
stimulator of the collagenase levels of adherent human rheumatoid synovial cells (42, 
43).  Also, LPS-treated adherent cells release IL-1  into the CM  (44). We have found 
as well that the adherent cells release IL-1 in response to T12 CWS (data not shown). 
However,  human IL-1  has  a  molecular weight  of ~13,000  by gel  chromatography 
(31). This would suggest that SA and IL-1 were distinct entities. In Table I, the SA 
activities  of  IL-1  preparations  of  different  degrees  of  purity  are  compared.  It  is 
apparent that as the specific activity of the IL- 1-containing samples increased (Stage 
I  to Stage  III) their SA activity declined, with the  most highly purified IL-1  tested 
(Stage III) having only weak SA activity. 
STABILITY OF THE SA ACTIVITY.  The pooled and concentrated peak of SA activity 1712  STREPTOCOCCAL  CELL  WALLS  AND  SYNOVIAL  CELL  ACTIVATION 
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FIG.  9.  Separation of SA activity from IFN-y and IL-2 activities by gel chromatography. Human 
synovial  fibroblasts  (6th  passage)  from  an  osteoarthritic  donor  (E.P.)  were  plated  in  l~sI-fibrin 
coated  wells,  and  the  PA  activity  measured after  a/8  h  in  the  presence of the  different  column 
fractions as in Fig.  8.  The fractions for SA assay were obtained as follows. IFN-y-containing CM 
was prepared by culturing peripheral blood [eukocytes at  I X  10  a cells/ml RPMI +  2% FBS for 72 
h  in the presence of 0.02 #g/ml SEB  (28).  The CM was partially purified by chromatography on 
controlled-pore glass and IFN-y containing fractions pooled  and lyophilised (28, 39). The sample 
(5 ml) was then applied to a  Sephadex G-100 column (2.6 cm X 50 cm) equilibrated with 20 mM 
sodium phosphate, 0.15 M  NaCI, pH 7 2;  5 ml fractions were collected at a  flow rate of 5 min/ml. 
Absorbance at 280 nm was recorded during the run. The molecular weight standards were as in Fig. 
8.  The mean fibrinolytic activity in  the wells containing the column buffer as control  was 4.2%. 
IFN-  7 and IL2 activities were quantitated as in Materials a~d Methods. 
TABLE  I 
SA Activity m 1L-I Samples of Different Degrees of Purity 
Degree of purification of IL- 1 sample  IL- 1 activity  Fibrinolysis 
added 
\ 
(1  % 
Stage I  0.8  8 
(10-50,000-mol wt fraction)  3.2  1"7 
Stage II  1.0  5 
(IEF-purified)  4.0  7 
Stage III  0.9  3 
(PAGE purified)  3.6  5 
Buffer (PBS)  --  3 
Human synovial fibroblasts (6th passage), from an osteoarthritic donor (LF.), 
were plated  in  12'~I-fibrin-coated  wells (Materials and Methods). After 48  h, 
the cultures were washed twice  with a-MEM  and placed  in a-MEM  +  5% 
ATFBS  containing  two  concentrations  of each  of the  three  different  IL-1 
preparations  (Materials and Methods). Aliquots of the supernatant medium 
were removed from the duplicate cultures at 24 h and assayed for solubilized 
radioactivity as a  measure of the fihrinolytic activity. HAMILTON, ZABRISKIE,  LACHMAN,  AND  CHEN  1713 
from the Sephadex G-100 column (Fig. 8)  (see Materials and Methods) was used for 
the following tests: 
(a) Temperature and pH.  The SA activity was stable at 4°C and 37°C for 24 h, 
only partially destroyed by  70°C  after  1 h  and  boiling  for 2  rain,  but  completely 
destroyed by boiling for 10 min. In addition, there was only slight loss of activity after 
three cycles of freezing at -70°C and thawing. No loss of SA activity was observed at 
pH 2-10 overnight at 4°C. 
(b)  2-Mercaptoethanol.  SA activity was retained after incubation for  10 rain at 
37°C with 0.1  M  2-mercaptoethanol, followed by dialysis. 
(c) Enzyme treatment.  After incubation with trypsin (Trypsin-TPCK, Worthing- 
ton  Biochemical Corp.,  Freehold, NJ)  (100/~g/ml,  0.1  M  Tris, pH  8.1)  for  1 h  at 
37°C,  ~70%  of  the  SA  activity  remained,  whereas  for  a-chymotrypsin  (Sigma 
Chemical  Co.,  St.  Louis,  MO)  (1  mg/ml,  0.1  M  Tris,  pH  8.1)  only  ~25%  of the 
activity was left. SA does not seem to be a  serine protease, as phenylmethylsulfonyl 
fluoride did not block its activity (11). The activity was stable after treatment with 
neuraminidase  (0.1  U/ml,  1  M  acetate  buffer,  pH  5.0)  for  1  h  at  37°C.  These 
treatments  suggest  that  the  SA  activity  is  protein  in  nature  without  functionally 
important  sialic  acid  residues  although,  of course,  the  sialic  acid  residues  may be 
inaccessible to the  neuraminidase  action.  More recent results  indicate that  the SA 
activity does not bind to a Con A-Sepharose affinity column (data not shown). 
Discussion 
In a previous publication (11), it was found that PBMC, particularly after Con A 
treatment, liberated an activity that increased the PA activity of passaged, nonrheu- 
matoid  human  synovial  fibroblasts.  We  have demonstrated  above that  MDP  and 
CWS preparations from group A streptococci are capable of eliciting the SA activity. 
There are other in vitro systems (see below) that study the MC modulation ofsynovial 
cell function as models for RA, but this is the first report in which an arthritogenic 
agent  (and one that has been implicated in human disease [2-5]) has been shown to 
potentiate the MC effect. 
It should be noted, however, that with a few PBMC populations, almost maximum 
SA activity was achieved in the absence of any exogenous stimulus. FBS (> 1%), even 
though having inhibitors that can block the PA activity during assay (20), is generally 
stimulatory by itself (Fig.  1), and  in some cases very little increase above the  FBS 
value is attained with any of the agents tested. In other words, dramatic increases can 
be obtained in most cases with CWS, Con A, and PHA, but sometimes the serum-free 
or FBS-containing control cultures can also have significant activity. As mentioned, 
LPS is stimulatory and could be present in some of the sample solutions being tested 
for stimulatory activity (44); however, this does not seem to be generally the case, as 
preincubation at room temperature for 3 h of the CWS, Con A, PHA, and FBS stock 
solutions with 50/xg/ml polymyxin B  (4:4) did not  reverse their effects, although  it 
successfully reversed the LPS effect for doses of LPS ~100 ng/mi. 
Although culture conditions were made as reproducible as possible in the present 
study,  different  synovial  fibroblast  lines  at  various  passage  numbers  were  used  as 
target cells for the monitoring of the SA activity. This approach permits an evaluation 
to be made of the extent of the variation in the system due to nature of the synovial 
donor; however, it should also be borne in mind that the PA activities from other cell 1714  STREPTOCOCCAL  CELL WALLS AND SYNOVIAL CELL ACTIVATION 
types  have  been  demonstrated  to  be  under  the  control  of a  number  of variables, 
including  serum  growth  rate  and  cell  density  (45).  Some of these  variables  have 
recently been discussed with particular reference to human synovial fibroblast lines, z 
For these reasons, the absolute PA activities should not be compared between different 
experiments, but rather the relative activities within an experiment considered. 
As mentioned in Results,  the data are consistent with the monocyte-macrophage 
cell class being the cells responsible for SA activity. In addition, several workers have 
strong evidence that both streptococcal peptidoglycans and MDP can act directly on 
monocyte-macrophages to alter both  cellular function and  product  formation  (for 
example see refs. 46-48). However, a few residual lymphocytes could be contributing 
to the SA levels, and there might also be some cellular interactions between lympho- 
cyte and macrophages. These questions might best be answered by enrichment and 
depletion of cell populations with monoclonal antibodies specific for PBMC subpop- 
ulations, which could enable a more definitive separation of the responsible cell types. 
The observation that MDP could generate SA activity suggests that it is the active 
principle in  the CWS,  a  finding consistent  with  previous studies on the biological 
properties of streptococcal and  other bacterial cell wall preparations  (32,  33). This 
result  would  suggest  that  phagocytosis  might  not  be  the  primary  trigger  for  SA 
generation by the CWS samples, but rather that there might be a critical interaction 
of the  peptidoglycan  moiety  with  the  monocyte-macrophage  membrane.  In  this 
regard, it has been found that readily phagocytized latex particles (1-~m Diam) were 
poor stimulators of SA activity (unpublished observations) and, as mentioned above, 
there  were  several  active  agents,  namely  PHA,  Con  A,  and  LPS,  which  were 
presumably functioning independently of a phagocytic mechanism. 
Other preliminary results have shown  that  streptococcal membrane preparations 
(obtained as in ref. 49)  are as active, on a  direct-weight basis, as the corresponding 
CWS preparation in releasing SA activity from the PBMC (unpublished observations). 
Because the bacterial membrane samples contain very low amounts of peptidoglycan 
(49), other bacterial components can be stimulatory besides the peptidoglycan moiety. 
However, the importance of the CWS stimulation may be in the observation that it 
is these structures and not the membrane that cause experimental arthritis  (7). The 
difference in biological activity may be due to the known persistence (nonbiodegrad- 
ability)  of cell  walls  (6,  7)  when  compared  with  membranes.  Current  studies  are 
directed  towards  determining  both  the  range  of streptococcal  groups  and  other 
bacterial strains that are active in the system. 
On the basis of biochemical data, it has been proposed that the mononuclear cell 
factor, which elevates the latent collagenase activity of rheumatoid cell cultures, is 
identical to IL-1  (42, 43); the preliminary biochemical evidence above indicates that 
SA activity(ies) is distinct from IL-1, IL-2, and IFN-y. The molecular weight estimate 
from gel chromatography (~30,000)  may be, of course, the result of aggregation or 
association  with  contaminant  proteins;  dissociating  conditions  may  yield  a  lower 
value. Also,, it cannot be assumed that the SA activity(ies) prepared under different 
culture conditions and with different stimuli will always have identical biochemical 
properties. The SA would seem to be different also from connective tissue activating 
peptide I, which is extracted from human spleen cells (50). This molecule stimulates 
hyaluronic acid production from human synovial fibroblasts but by Sephadex G-100 
chromatography has a  molecular weight of ~ 15,000  (50).  But again,  more detailed HAMILTON, ZABRISKIE, LACHMAN, AND CHEN  1715 
biochemical analysis is necessary before the nonidentity can be stated with certainty, 
particularly as crude MCCM also stimulate hyaluronic acid levels (data not shown). 
We would like to suggest that  the in vitro human model system described in the 
present  paper  has  several  features consistent  with  those of the  rat  arthritis  model 
established by intraperitoneal injection of group A streptococci CWS (7, 8). Histologic 
features of this arthritis  included an  acute exudative phase followed by an erosive 
synovitis  that  led  to  destruction  of cartilage  and  subchondral  bone,  and  fibrous 
ankylosis of the joints. The responsible moiety seemed to be a peptidoglycan-polysac- 
charide fragment of the cell well that persisted in tissue, with much of this material 
localized within macrophages (7, 8). We have shown above that group A streptococcal 
CWS interact with monocyte-macrophages to elicit an activity capable of stimulating 
synovial  cells  to  elaborate,  in  turn,  a  protease  system  (PA/plasmin)  capable  of 
contributing to some of the invasive, destructive, and  inflammatory processes in an 
arthritic joint  (see  introduction).  Seeing  that  high  PA  activity  often  results  after 
oncogenic transformation of fibroblasts (20), it was proposed previously (11)  that the 
mononuclear cell-mediated change in the synovial cell metabolism is consistent with 
some of the morphological descriptions of the pannus  as "tumor-like" (51,  52)  and 
also "aggressive and, in a sense, malignant," (53). It is not our intention to minimize 
the  possible  direct  role  of inflammatory  cells  themselves  in  the  destructive  and 
inflammatory events  in  the  RA joint,  but  we  propose that  the  modified synovial 
fibroblast cell could also be important (see also refs. 23, 52). 
It  would seem  imperative in  future studies  to search  for the presence of the SA 
activity in rheumatoid fluids, in CM from tissue, and also in animal model systems as 
a test of the relevance of the above proposal to disease. Future work will also examine 
the possible involvement of lymphocyte-macrophage interaction in the elicitation of 
SA  activity,  particularly  as  such  an  interaction  involving  streptococcal  cell  wall 
antigen  presentation  might  be  relevant  to  an  understanding  of the  likely genetic 
component of RA (54). 
Summary 
Group A streptococcal peptidoglycan has previously been shown to be arthritogenic 
in rats and has been implicated as a  structure present in a class of possible etiologic 
agents for rheumatoid arthritis. The present study reports that conditioned medium 
from human  monocytes, after interaction with cell wall sonicates of four group A 
streptococcal strains, stimulates the plasminogen activator (PA) activity of nonrheu- 
matoid synovial fibroblasts.  Low concentrations of N-acetylmuramyl-L-alanyl-D iso- 
glutamine (muramyl dipeptide) can also generate this synovial activator (SA) activity 
from human monocytes. Preliminary biochemical data suggest that the SA activity is 
distinct from interferon-y, interleukin 1, and interleukin 2. These results indicate that 
agents that are arthritogenic in rats can modulate human synovial fibroblast functions 
via  monocytes.  The  findings  are  proposed  to  have  possible  significance  for  an 
understanding of the cellular interactions involved in the formation and function of 
the  rheumatoid  pannus,  because PA  has  been  invoked as  possibly being generally 
important for the processes of cell migration, tissue remodeling, and inflammation. 
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